Evidence map›Paper›PMID 32619831›Full record

ArticleCancer treatment and research communications2020

Antibody selection influences the detection of AR-V7 in primary prostate cancer.

Adam Kaczorowski, Xin Chen, Esther Herpel, Axel S Merseburger, Glen Kristiansen, Christof Bernemann, Markus Hohenfellner, Marcus V Cronauer, Stefan Duensing

Open access · goldAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cancer treatment and research communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Adam KaczorowskiMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, Heidelberg, D-69120, Germany.
Xin ChenMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, Heidelberg, D-69120, Germany.
Esther HerpelInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, Heidelberg, D-69120, Germany; Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 224, Heidelberg, D-69120, Germany.
Axel S MerseburgerDepartment of Urology, University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, Lübeck, D-23538, Germany.
Glen KristiansenInstitute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, Bonn, D-53127, Germany.
Christof BernemannDepartment of Urology, University Hospital Münster, Albert-Schweitzer Campus 1, Münster, D-48149, Germany.
Markus HohenfellnerDepartment of Urology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, Heidelberg, D-69120, Germany.
Marcus V CronauerDepartment of Urology, University Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, Lübeck, D-23538, Germany; Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, Bonn, D-53127, Germany. Electronic address: marcus.cronauer@ukbonn.de.
Stefan DuensingMolecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, Heidelberg, D-69120, Germany; Department of Urology, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 110, Heidelberg, D-69120, Germany. Electronic address: stefan.duensing@med.uni-heidelberg.de.
Heidelberg University · DEUniversity Hospital Bonn · DEUniversity Hospital Heidelberg · DENational Center for Tumor Diseases · DEUniversity Hospital Münster · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown that a subset of patients also express AR-V7 in the primary tumor. These findings have recently been challenged by a study showing that AR-V7 becomes only detectable in CRPC but is virtually absent in castration-naïve prostate cancer.

methodsHerein, we directly compare the two relevant antibodies used for the immunodetection of AR-V7 in the conflicting studies (clones AG10008 and RM7) in a predominantly high-risk prostate cancer patient cohort with primary tumor specimens assembled in a tissue microarray (TMA).

resultsThe overall rate of AR-V7 positive TMA cores was comparable (AG10008, 24.9%; RM7, 21%). However, the percentage agreement of identical staining intensities of positive cores was only 7%. In contrast, the percentage agreement of negative cores was 62.8%. In approximately 30% of the cores, the antibodies produced discordant staining intensities. Only one of the two antibody stainings (AG10008) conveyed prognostic information and was associated with a shorter progression-free patient survival.

conclusionsOur study underscores that nuclear AR-V7 expression can be detected in primary prostate cancer prior to long-term androgen deprivation and castration resistance. There are staining differences between the two antibodies in tumor tissue, for which we currently have no explanation. Clearly, improvements in the detection of functional AR-V7 in prostate cancer are urgently needed.

Indexed as

Androgen Receptor AntagonistsAntibodies, MonoclonalBiomarkers, TumorCell NucleusClinical Decision-MakingDisease-Free SurvivalHumansImmunohistochemistryMalePrognosisProgression-Free SurvivalProstateProstatic Neoplasms, Castration-ResistantProtein IsoformsReceptors, AndrogenSensitivity and SpecificityAndrogen Receptor AntagonistsAntibodies, MonoclonalAR protein, humanBiomarkers, TumorProtein IsoformsReceptors, AndrogenAR-V7Prostate cancer

Identifiers

PMID32619831
OpenAlexW3038105804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.